

assistance and Jenna Rychert for assistance with sample identification. Acute/early-infected patients were recruited through the Acute Infection and Early Disease Research Program (AIEDRP) network from sites in the United States and the National Centre in HIV Epidemiology and Clinical Research (NCHECR) Primary Infection Network in Sydney, Australia, by Robert Finlayson (Taylor Square Clinic, Darlinghurst) and Robert MacFarland (East Sydney Doctors, Darlinghurst).

This project was supported by grants from the Canadian Institutes for Health Research (CIHR) (to Z.L.B. and M.A.B.), the National Institutes of Health (grants AI028568, AI030914, AI074415, AI054178, and AI071915) (to B.D.W., T.M.A., M.A., and E.R.), the Howard Hughes Medical Institute, the Bill and Melinda Gates Foundation (to B.D.W. and T.M.A.), and the Harvard University Center for AIDS Research. Z.L.B. is a CIHR New Investigator Award recipient. C.J.B. is supported by an NSERC Julie Payette graduate scholarship. A.D.K. is supported by a program grant and practitioner fellowship from the Australian National Health and Medical Research Council. The NCHECR is supported by the Australian Commonwealth Department of Health and Ageing.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions expressed here are solely the responsibility of the authors and do not necessarily represent those held by their respective institutions or funding agencies.

M.A.B., Z.L.B., T.M., B.D.W., and T.M.A. designed this study. M.A.B., Z.L.B., J.S., P.C.R., and T.J.M. conducted experiments and analyzed data. C.J.B., C.M.K., J.M.C., and D.H. developed statistical methods and/or contributed to data analysis. H.S., A.D.K., H.J., E.R., M.M., M.A., and P.R.H. contributed specimens and/or clinical data. The manuscript was written by M.A.B. and Z.L.B. and critically reviewed by C.J.B., T.M., T.J.M., H.S., A.D.K., M.M., H.J., E.R., M.A., P.R.H., B.D.W., and T.M.A.

REFERENCES

- Allen, T. M., and M. Altfeld. 2008. Crippling HIV one mutation at a time. *J. Exp. Med.* 205:1003–1007.
- Allen, T. M., D. H. O'Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, K. J. Kunstman, X. Wang, D. B. Allison, A. L. Hughes, R. C. Desrosiers, J. D. Altman, S. M. Wolinsky, A. Sette, and D. I. Watkins. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. *Nature* 407:386–390.
- Avila-Rios, S., C. E. Ormsby, J. M. Carlson, H. Valenzuela-Ponce, J. Blanco-Heredia, D. Garrido-Rodriguez, C. Garcia-Morales, D. Heckerman, Z. L. Brumme, S. Mallal, M. John, E. Espinosa, and G. Reyes-Teran. 2009. Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study. *Retrovirology* 6:72.
- Barouch, D. H., K. L. O'Brien, N. L. Simmons, S. L. King, P. Abbink, L. F. Maxfield, Y. H. Sun, A. La Porte, A. M. Riggs, D. M. Lynch, S. L. Clark, K. Backus, J. R. Perry, M. S. Seaman, A. Carville, K. G. Mansfield, J. J. Szinger, W. Fischer, M. Muldoon, and B. Korber. 2010. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. *Nat. Med.* 16:319–323.
- Barrie, K. A., E. E. Perez, S. L. Lamers, W. G. Farmerie, B. M. Dunn, J. W. Sleasman, and M. M. Goodenow. 1996. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. *Virology* 219:407–416.
- Borrow, P., H. Lewicki, B. H. Hahn, G. M. Shaw, and M. B. Oldstone. 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. *J. Virol.* 68:6103–6110.
- Borrow, P., H. Lewicki, X. Wei, M. S. Horwitz, N. Pfeffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. H. Hahn, M. B. Oldstone, and G. M. Shaw. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. *Nat. Med.* 3:205–211.
- Boutwell, C. L., and M. Essex. 2007. Identification of HLA class I-associated amino acid polymorphisms in the HIV-1C proteome. *AIDS Res. Hum. Retroviruses* 23:165–174.
- Boutwell, C. L., C. F. Rowley, and M. Essex. 2009. Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. *J. Virol.* 83:2460–2468.
- Brockman, M. A., A. Schneidewind, M. Lahaie, A. Schmidt, T. Miura, I. Desouza, F. Ryvkin, C. A. Derdeyn, S. Allen, E. Hunter, J. Mulenga, P. A. Goepfert, B. D. Walker, and T. M. Allen. 2007. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. *J. Virol.* 81:12608–12618.
- Brumme, Z. L., C. J. Brumme, J. Carlson, H. Streeck, M. John, Q. Eichbaum, B. L. Block, B. Baker, C. Kadie, M. Markowitz, H. Jessen, A. D. Kelleher, E. Rosenberg, J. Kaldor, Y. Yuki, M. Carrington, T. M. Allen, S. Mallal, M. Altfeld, D. Heckerman, and B. D. Walker. 2008. Marked epitope and allele-specific differences in rates of mutation in HIV-1 Gag, Pol and Nef CTL epitopes in acute/early HIV-1 infection. *J. Virol.* 82:9216–9227.
- Brumme, Z. L., C. J. Brumme, C. Chui, T. Mo, B. Wynhoven, C. K. Woods, B. M. Henrick, R. S. Hogg, J. S. Montaner, and P. R. Harrigan. 2007. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. *J. Infect. Dis.* 195:1694–1704.
- Brumme, Z. L., C. J. Brumme, D. Heckerman, B. T. Korber, M. Daniels, J. Carlson, C. Kadie, T. Bhattacharya, C. Chui, J. Szinger, T. Mo, R. S. Hogg, J. S. Montaner, N. Frahm, C. Brander, B. D. Walker, and P. R. Harrigan. 2007. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. *PLoS Pathog.* 3:e94.
- Brumme, Z. L., M. John, J. M. Carlson, C. J. Brumme, D. Chan, M. A. Brockman, L. C. Swenson, I. Tao, S. Szeto, P. Rosato, J. Sela, C. M. Kadie, N. Frahm, C. Brander, D. W. Haas, S. Riddler, R. Haubrich, B. D. Walker, P. R. Harrigan, D. Heckerman, and S. Mallal. 2009. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. *PLoS One* 4:e6687.
- Carlson, J. M., Z. L. Brumme, C. M. Rousseau, C. J. Brumme, P. Matthews, C. Kadie, J. I. Mullins, B. D. Walker, P. R. Harrigan, P. J. Goulder, and D. Heckerman. 2008. Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. *PLoS Comput. Biol.* 4:e1000225.
- Carrington, M., and S. J. O'Brien. 2003. The influence of HLA genotype on AIDS. *Annu. Rev. Med.* 54:535–551.
- Chopera, D. R., Z. Woodman, K. Misana, M. Mlotshwa, D. P. Martin, C. Seoighe, F. Treurnicht, D. A. de Rosa, W. Hide, S. A. Karim, C. M. Gray, and C. Williamson. 2008. Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. *PLoS Pathog.* 4:e1000033.
- Couillin, I., B. Culmann-Penciolelli, E. Gomard, J. Choppin, J. P. Levy, J. G. Guillet, and S. Saragosti. 1994. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein. *J. Exp. Med.* 180:1129–1134.
- Crawford, H., W. Lumm, A. Leslie, M. Schaefer, D. Boeras, J. G. Prado, J. Tang, P. Farmer, T. Ndung'u, S. Lakhji, J. Gilmour, P. Goepfert, B. D. Walker, R. Kaslow, J. Mulenga, S. Allen, P. J. Goulder, and E. Hunter. 2009. Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. *J. Exp. Med.* 206:909–921.
- Crawford, H., J. G. Prado, A. Leslie, S. Hue, I. Honeyborne, S. Reddy, M. van der Stok, Z. Mncube, C. Brander, C. Rousseau, J. I. Mullins, R. Kaslow, P. Goepfert, S. Allen, E. Hunter, J. Mulenga, P. Kiepiela, B. D. Walker, and P. J. Goulder. 2007. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. *J. Virol.* 81:8346–8351.
- Duda, A., L. Lee-Turner, J. Fox, N. Robinson, S. Dustan, S. Kaye, H. Fryer, M. Carrington, M. McClure, A. R. McLean, S. Fidler, J. Weber, R. E. Phillips, and A. J. Frater. 2009. HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. *J. Virol.* 83:1228–1239.
- Edwards, B. H., A. Bansal, S. Sabbaj, J. Bakari, M. J. Mulligan, and P. A. Goepfert. 2002. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. *J. Virol.* 76:2298–2305.
- Fiebig, E. W., D. J. Wright, B. D. Rawal, P. E. Garrett, R. T. Schumacher, L. Peddada, C. Heldebrandt, R. Smith, A. Conrad, S. H. Kleinman, and M. P. Busch. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. *AIDS* 17:1871–1879.
- Friedrich, T. C., E. J. Dodds, L. J. Yant, L. Vojnov, R. Rudersdorf, C. Cullen, D. T. Evans, R. C. Desrosiers, B. R. Mothe, J. Sidney, A. Sette, K. Kunstman, S. Wolinsky, M. Piatak, J. Lifson, A. L. Hughes, N. Wilson, D. H. O'Connor, and D. I. Watkins. 2004. Reversion of CTL escape-variant immunodeficiency viruses in vivo. *Nat. Med.* 10:275–281.
- Gao, X., A. Bashirova, A. K. Iversen, J. Phair, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, M. Altfeld, S. J. O'Brien, and M. Carrington. 2005. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. *Nat. Med.* 11:1290–1292.
- Gaschen, B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Novitsky, B. Haynes, B. H. Hahn, T. Bhattacharya, and B. Korber. 2002. Diversity considerations in HIV-1 vaccine selection. *Science* 296:2354–2360.
- Goepfert, P. A., W. Lumm, P. Farmer, P. Matthews, A. Prendergast, J. M. Carlson, C. A. Derdeyn, J. Tang, R. A. Kaslow, A. Bansal, K. Yusim, D.

- Heckerman, J. Mulenga, S. Allen, P. J. Goulder, and E. Hunter. 2008. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. *J. Exp. Med.* 205:1009–1017.
28. Goonetilleke, N., M. K. Liu, J. F. Salazar-Gonzalez, G. Ferrari, E. Giorgi, V. V. Ganusov, B. F. Keele, G. H. Learn, E. L. Turnbull, M. G. Salazar, K. J. Weinhold, S. Moore, N. Letvin, B. F. Haynes, M. S. Cohen, P. Hraber, T. Bhattacharya, P. Borrow, A. S. Perelson, B. H. Hahn, G. M. Shaw, B. T. Korber, and A. J. McMichael. 2009. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. *J. Exp. Med.* 206:1253–1272.
 29. Goulder, P. J., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, A. J. McMichael, and S. Rowland-Jones. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. *Nat. Med.* 3:212–217.
 30. Guindon, S., and O. Gascuel. 2003. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. *Syst. Biol.* 52:696–704.
 31. Honeyborne, I., A. Prendergast, F. Pereyra, A. Leslie, H. Crawford, R. Payne, S. Reddy, K. Bishop, E. Moodley, K. Nair, M. van der Stok, N. McCarthy, C. M. Rousseau, M. Addo, J. I. Mullins, C. Brander, P. Kiepiela, B. D. Walker, and P. J. Goulder. 2007. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. *J. Virol.* 81:3667–3672.
 32. Huang, X., and J. Zhang. 1996. Methods for comparing a DNA sequence with a protein sequence. *Comput. Appl. Biosci.* 12:497–506.
 33. Janssen, R. S., G. A. Satten, S. L. Stramer, B. D. Rawal, T. R. O'Brien, B. J. Weiblen, F. M. Hecht, N. Jack, F. R. Clegghorn, J. O. Kahn, M. A. Chesney, and M. P. Busch. 1997. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. *JAMA* 280:42–48.
 34. John, M., D. Heckerman, I. James, L. P. Park, J. M. Carlson, A. Chopra, S. Gaudieri, D. Nolan, D. Haas, S. A. Riddler, D. Haubrich, and S. Mallal. 2010. Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. *J. Immunol.* 184:4368–4377.
 35. Kelleher, A. D., C. Long, E. C. Holmes, R. L. Allen, J. Wilson, C. Conlon, C. Workman, S. Shaunak, K. Olson, P. Goulder, C. Brander, G. Ogg, J. S. Sullivan, W. Dyer, I. Jones, A. J. McMichael, S. Rowland-Jones, and R. E. Phillips. 2001. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. *J. Exp. Med.* 193:375–386.
 36. Kiepiela, P., K. Ngumbela, C. Thobakgale, D. Ramduth, I. Honeyborne, E. Moodley, S. Reddy, C. de Pierres, Z. Mncube, N. Mkhwanazi, K. Bishop, M. van der Stok, K. Nair, N. Khan, H. Crawford, R. Payne, A. Leslie, J. Prado, A. Prendergast, J. Frater, N. McCarthy, C. Brander, G. H. Learn, D. Nickle, C. Rousseau, H. Coovadia, J. I. Mullins, D. Heckerman, B. D. Walker, and P. J. Goulder. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. *Nat. Med.* 13:46–53.
 37. Koch, N., N. Yahi, J. Fantini, and C. Tamalet. 2001. Mutations in HIV-1 gag cleavage sites and their association with protease mutations. *AIDS* 15:526–528.
 38. Korber, B. T., N. L. Letvin, and B. F. Haynes. 2009. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. *J. Virol.* 83:8300–8314.
 39. Koup, R. A., J. T. Safrin, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. *J. Virol.* 68:4650–4655.
 40. Leslie, A. J., and P. J. Goulder. 2006. HIV escape and attenuation by cytotoxic T lymphocytes. *Curr. Opin. HIV AIDS* 1:34–39.
 41. Leslie, A. J., K. J. Pfafferoth, P. Chetty, R. Draenert, M. M. Addo, M. Feeney, Y. Tang, E. C. Holmes, T. Allen, J. G. Prado, M. Altfeld, C. Brander, C. Dixon, D. Ramduth, P. Jeena, S. A. Thomas, A. St. John, T. A. Roach, B. Kupfer, G. Luzzi, A. Edwards, G. Taylor, H. Lyall, G. Tudor-Williams, V. Novelli, J. Martinez-Picado, P. Kiepiela, B. D. Walker, and P. J. Goulder. 2004. HIV evolution: CTL escape mutation and reversion after transmission. *Nat. Med.* 10:282–289.
 42. Martinez-Picado, J., J. G. Prado, E. E. Fry, K. Pfafferoth, A. Leslie, S. Chetty, C. Thobakgale, I. Honeyborne, H. Crawford, P. Matthews, T. Pillay, C. Rousseau, J. I. Mullins, C. Brander, B. D. Walker, D. I. Stuart, P. Kiepiela, and P. J. Goulder. 2006. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. *J. Virol.* 80:3617–3623.
 43. Matthews, P. C., A. Prendergast, A. Leslie, H. Crawford, R. Payne, C. Rousseau, M. Rolland, I. Honeyborne, J. Carlson, C. Kadie, C. Brander, K. Bishop, N. Mlotshwa, J. D. Mullins, H. Coovadia, T. Ndung'u, B. D. Walker, D. Heckerman, and P. J. Goulder. 2008. Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. *J. Virol.* 82:8548–8559.
 44. McMichael, A. J., P. Borrow, G. D. Tomaras, N. Goonetilleke, and B. F. Haynes. 2010. The immune response during acute HIV-1 infection: clues for vaccine development. *Nat. Rev. Immunol.* 10:11–23.
 45. McMichael, A. J., and R. E. Phillips. 1997. Escape of human immunodeficiency virus from immune control. *Annu. Rev. Immunol.* 15:271–296.
 46. Miura, T., M. A. Brockman, C. J. Brumme, Z. L. Brumme, J. M. Carlson, F. Pereyra, A. Trocha, M. M. Addo, B. L. Block, A. C. Rothchild, B. M. Baker, T. Flynn, A. Schneidewind, B. Li, Y. E. Wang, D. Heckerman, T. M. Allen, and B. D. Walker. 2008. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. *J. Virol.* 82:8422–8430.
 47. Miura, T., M. A. Brockman, Z. L. Brumme, C. J. Brumme, F. Pereyra, A. Trocha, B. L. Block, A. Schneidewind, T. M. Allen, D. Heckerman, and B. D. Walker. 2009. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-Protease from elite controllers of human immunodeficiency virus type 1. *J. Virol.* 83:140–149.
 48. Miura, T., M. A. Brockman, A. Schneidewind, M. Lobritz, F. Pereyra, A. Rathod, B. L. Block, Z. L. Brumme, C. J. Brumme, B. Baker, A. C. Rothchild, B. Li, A. Trocha, E. Cutrell, N. Frahm, C. Brander, I. Toth, E. J. Arts, T. M. Allen, and B. D. Walker. 2009. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition. *J. Virol.* 83:2743–2755.
 49. Miura, T., Z. L. Brumme, M. Brockman, P. Rosato, J. Sela, C. J. Brumme, F. Pereyra, D. E. Kaufmann, A. Trocha, B. L. Block, E. S. Daar, E. Connick, H. Jessen, A. D. Kelleher, E. Rosenberg, M. Markowitz, K. Schafer, F. Vaida, A. Iwamoto, S. Little, and B. D. Walker. 2010. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. *J. Virol.* 84:7581–7591.
 50. Moore, C. B., M. John, I. R. James, F. T. Christiansen, C. S. Witt, and S. A. Mallal. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. *Science* 296:1439–1443.
 51. O'Brien, S. J., X. Gao, and M. Carrington. 2001. HLA and AIDS: a cautionary tale. *Trends Mol. Med.* 7:379–381.
 52. Peyrel, F. W., H. S. Bazick, M. H. Newberg, D. H. Barouch, J. Sodroski, and N. L. Letvin. 2004. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. *J. Virol.* 78:13901–13910.
 53. Prado, J. G., I. Honeyborne, I. Brierley, M. C. Puentes, J. Martinez-Picado, and P. J. Goulder. 2009. Functional consequences of human immunodeficiency virus escape from an HLA-B*13-restricted CD8+ T-cell epitope in p1 Gag protein. *J. Virol.* 83:1018–1025.
 54. Price, D. A., P. J. Goulder, P. Klenerman, A. K. Sewell, P. J. Easterbrook, M. Troop, C. R. Bangham, and R. E. Phillips. 1997. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. *Proc. Natl. Acad. Sci. U. S. A.* 94:1890–1895.
 55. Rolland, M., D. C. Nickle, and J. I. Mullins. 2007. HIV-1 group M conserved elements vaccine. *PLoS Pathog.* 3:e157.
 56. Rousseau, C. M., M. G. Daniels, J. M. Carlson, C. Kadie, H. Crawford, A. Prendergast, P. Matthews, R. Payne, M. Rolland, D. N. Raugi, B. S. Maust, G. H. Learn, D. C. Nickle, H. Coovadia, T. Ndung'u, N. Frahm, C. Brander, B. D. Walker, P. J. Goulder, T. Bhattacharya, D. E. Heckerman, B. T. Korber, and J. I. Mullins. 2008. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype C proteome: immune escape and viral load. *J. Virol.* 82:6434–6446.
 57. Rowland-Jones, S. L., R. E. Phillips, D. F. Nixon, F. M. Gotch, J. P. Edwards, A. O. Ogunlesi, J. G. Elvin, J. A. Rothbard, C. R. Bangham, C. R. Rizza, et al. 1992. Human immunodeficiency virus variants that escape cytotoxic T-cell recognition. *AIDS Res. Hum. Retroviruses* 8:1353–1354.
 58. Schneidewind, A., M. A. Brockman, J. Sidney, Y. E. Wang, H. Chen, T. J. Suscovich, B. Li, R. I. Adam, R. L. Allgaier, B. R. Mothe, T. Kuntzen, C. Oniangue-Ndza, A. Trocha, X. G. Yu, C. Brander, A. Sette, B. D. Walker, and T. M. Allen. 2008. Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. *J. Virol.* 82:5594–5605.
 59. Schneidewind, A., M. A. Brockman, R. Yang, R. I. Adam, B. Li, S. Le Gall, C. R. Rinaldo, S. L. Craggs, R. L. Allgaier, K. A. Power, T. Kuntzen, C. S. Tung, M. X. LaBute, S. M. Mueller, T. Harrer, A. J. McMichael, P. J. Goulder, C. Aiken, C. Brander, A. D. Kelleher, and T. M. Allen. 2007. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. *J. Virol.* 81:12382–12393.
 60. Storey, J. D., and R. Tibshirani. 2003. Statistical significance for genomewide studies. *Proc. Natl. Acad. Sci. U. S. A.* 100:9440–9445.
 61. Taylor, B. S., and S. M. Hammer. 2008. The challenge of HIV-1 subtype diversity. *N. Engl. J. Med.* 359:1965–1966.
 62. Troyer, R. M., J. McNevin, Y. Liu, S. C. Zhang, R. W. Krizan, A. Abrahama, D. M. Tebit, H. Zhao, S. Avila, M. A. Lobritz, M. J. McElrath, S. Le Gall, J. I. Mullins, and E. J. Arts. 2009. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. *PLoS Pathog.* 5:e1000365.
 63. Wang, Y. E., B. Li, J. M. Carlson, H. Streeck, A. D. Gladden, R. Goodman, A. Schneidewind, K. A. Power, I. Toth, N. Frahm, G. Alter, C. Brander, M. Carrington, B. D. Walker, M. Altfeld, D. Heckerman, and T. M. Allen. 2009. Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses

- are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. *J. Virol.* **83**:1845–1855.
64. Wright, J. K., Z. L. Brumme, J. M. Carlson, D. Heckerman, C. M. Kadie, C. J. Brumme, B. Wang, E. Losina, T. Miura, F. Chonco, M. van der Stok, Z. Mncube, K. Bishop, P. J. R. Goulder, B. D. Walker, M. A. Brockman, and T. Ndung'u. 2010. Gag-Protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. *J. Virol.* **84**:10820–10831.
65. Yeh, W. W., E. M. Cale, P. Jaru-Ampornpan, C. I. Lord, F. W. Peyerl, and N. L. Letvin. 2006. Compensatory substitutions restore normal core assembly in simian immunodeficiency virus isolates with Gag epitope cytotoxic T-lymphocyte escape mutations. *J. Virol.* **80**:8168–8177.
66. Zuniga, R., A. Lucchetti, P. Galvan, S. Sanchez, C. Sanchez, A. Hernandez, H. Sanchez, N. Frahm, C. H. Linde, H. S. Hewitt, W. Hildebrand, M. Altfield, T. M. Allen, B. D. Walker, B. T. Korber, T. Leitner, J. Sanchez, and C. Brander. 2006. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. *J. Virol.* **80**:3122–3125.

